Why is it a critical mistake for HealthTech founders to base their go-to-market strategy on a broad customer category like 'healthcare' instead of their specific business model, such as subscriptions or B2B sales?

Aligning your go-to-market strategy with your business model, not just your customer type, is the most crucial decision a HealthTech founder can make. The way you earn revenue dictates your entire commercial system, from sales cycle and team structure to the metrics that matter. A consumer telemedicine app and a hospital SaaS platform both serve 'healthcare', but their paths to scale are fundamentally different and require separate playbooks. Mixing them leads to wasted capital and stalled growth. Your business model determines the GTM system you need to build: Digital Health Platforms: With revenue from transaction fees and subscriptions, the GTM must solve for a low initial order value. The focus is on driving repeat purchases through retention mechanics like refill reminders and loyalty credits to recover an acquisition cost of Rs 1,500 to Rs 3,500 per customer.Telehealth: Revenue comes from consultations or packages. The GTM challenge is turning a single interaction into a habit. Success depends on features like unlimited plans and stored records to build long-term patient relationships.B2B Hospital Sales: Based on annual contracts, this model requires a GTM that can navigate a 6 to 19 month sales cycle and gain consensus from up to 10 stakeholders. The focus is on demonstrating clinical outcomes and achieving workflow lock-in. Failing to build your GTM around these distinct economic realities is the most common reason healthtech companies fail to scale. Discover how to match your commercial strategy to your revenue structure in the complete guide.

The guide highlights that HealthTech GTM is the system built around a revenue model. Can you explain what this means in practice and why it prevents founders from running a consumer playbook for enterprise buyers?

Defining your HealthTech GTM as a system built around your revenue model means every commercial choice is a direct consequence of how you make money. This concept prevents catastrophic mistakes, like applying fast, high-volume consumer tactics to the slow, relationship-driven world of B2B hospital sales. The unit economics, sales motion, and scaling dynamics are completely different, and your GTM must reflect that reality. It is a framework for ensuring your spending, hiring, and strategic focus are aligned with your economic engine. A revenue-model-first GTM approach creates clarity. For instance, consider a consumer wellness app versus a hospital SaaS tool: The Consumer Playbook (Wellness App): Optimizes for a short sales cycle (days to weeks) and a low acquisition cost (Rs 2,500 to Rs 4,000). The team is heavy on performance marketers and product managers who build retention loops. Success is measured in monthly active users and lifetime value.The Enterprise Playbook (Hospital SaaS): Optimizes for a long sales cycle (6 to 19 months) and deep, trust-based relationships. The team is composed of enterprise sales executives and clinical experts. Success is measured in annual contract value and pilot-to-contract conversion rates. Running a consumer playbook on an enterprise target means you would burn through capital on ads while failing to build the necessary stakeholder consensus. Learn more about designing the right system for your model.

For a founder choosing between a direct-to-consumer digital health platform and a B2B hospital sales model, how do the core GTM challenges and unit economics compare, and what factors should guide the decision?

The choice between a direct-to-consumer platform and a B2B hospital sales model presents a stark contrast in go-to-market strategy, primarily revolving around volume versus value. A digital health platform pursues millions of small, quick transactions, while a B2B model chases a few large, slow-to-close contracts. Your decision should be guided by your team's expertise, your access to capital, and your product's core value proposition. Here is how the two models stack up on key GTM dimensions: Sales Cycle: Digital health platforms measure their sales cycle in days or weeks. B2B hospital sales take 6 to 19 months to close, requiring significant patience and runway.Acquisition Cost (CAC): The CAC for a consumer platform is relatively low, estimated by upGrowth at Rs 1,500 to Rs 3,500. In contrast, landing a single B2B hospital deal can cost between Rs 8 lakh and Rs 15 lakh.Core GTM Challenge: For consumer platforms, the main hurdle is overcoming low initial order values by engineering repeat purchases. For B2B sales, the challenge is achieving consensus among 6 to 10 stakeholders and managing complex integration risks. Your selection of business model has massive downstream implications for headcount and budgeting. This comparison provides a starting point for aligning your strategy with your goals.

The content mentions that for digital health platforms, the first order rarely pays for itself. Using examples like e-pharmacies, how do successful companies design their GTM to overcome this economic challenge and achieve profitability?

Successful digital health platforms achieve profitability by accepting that the first transaction is a loss leader and building a GTM system entirely focused on the second purchase and beyond. They treat customer acquisition not as a single event but as an investment that pays off over time through high retention and increased lifetime value (LTV). For an e-pharmacy, where the acquisition cost can be Rs 1,200 to Rs 2,000, the strategy is to make reordering almost automatic. The GTM is engineered to create habits and reduce friction for repeat engagement. Proven strategies include: Refill Subscriptions and Reminders: These features automate the reordering process for chronic medications, turning a one-time purchase into a predictable revenue stream and locking in the customer.Loyalty Credits and Bundled Offers: Rewarding repeat customers with credits or offering discounts on related wellness products increases the average order value over time, accelerating the payback period on the initial acquisition cost.Stored Health Records and Personalized Content: By becoming the system of record for a user's health data, platforms create stickiness and provide value beyond the transaction, making it less likely for a customer to switch. These tactics shift the focus from a single sale to building a long-term health relationship, which is the only sustainable path to positive unit economics. Explore more retention drivers in our detailed analysis.

The data shows B2B hospital sales have an extremely long sales cycle of 6 to 19 months. What specific GTM strategies have proven effective for companies navigating this timeline to secure high-value annual contracts?

Companies that succeed in B2B hospital sales build their GTM strategy around patience, proof, and process, directly addressing the long sales cycle and multi-stakeholder complexity. Instead of pushing for a quick close, they focus on de-risking the decision for the hospital by demonstrating tangible value at every stage. The key is to treat the 6 to 19 month cycle as a journey of building consensus, not a transactional sale. A GTM designed for this environment prioritizes deep relationship-building and clinical validation over high-volume outreach. Effective strategies for managing this extended sales process include: Building Clinical Credibility: Leading with data from pilot programs and clinical studies that prove improved outcomes or workflow efficiencies. This provides the evidence needed for clinical champions to advocate for your solution internally.Multi-Stakeholder Mapping and Engagement: Proactively identifying and building relationships with all 6 to 10 decision-makers, from department heads and clinicians to IT security and procurement. Each has different concerns that must be addressed.Focusing on Integration and Workflow Lock-in: Demonstrating how your solution seamlessly integrates with existing hospital systems (like EHRs) minimizes disruption and creates high switching costs, which is a powerful incentive for securing a long-term contract. This methodical, evidence-based approach aligns with the risk-averse nature of healthcare institutions. See how to structure your team and budget for this model in the full breakdown.

For a new direct-to-consumer telehealth company, what is the ideal, step-by-step process for building a go-to-market plan that turns single consultations into long-term, profitable patient relationships from the outset?

A new telehealth company must build its GTM plan around habit formation, as a single consultation is rarely profitable. The goal is to design a system that encourages repeat usage and transforms a transactional user into a loyal patient. This requires a deliberate focus on the user experience and retention mechanics right from launch, ensuring your acquisition spend generates long-term value. Follow this four-step process to build a retention-focused GTM: Define Your Retention-Centric Offer: Before acquiring users, decide on the core retention driver. Will it be an 'unlimited consultations' subscription package, a tightly integrated pharmacy for seamless prescription fulfillment, or corporate packages that lock in entire employee groups?Optimize Acquisition for the Right Patient: Focus marketing spend on channels that attract patients with chronic or recurring needs, not just those seeking a one-off consultation. Your target acquisition cost should be in the Rs 1,200 to Rs 2,500 range, which is only viable with repeat business.Build Stickiness into the Product: Make your platform the central hub for a patient's health. Implement features like easily accessible stored medical records, follow-up reminders with the same doctor, and personalized health content to create lock-in.Measure for Lifetime Value: Your primary key performance indicators should be consultation frequency, repeat patient rate, and customer lifetime value (LTV). These metrics, rather than just the number of initial sign-ups, will show if your GTM is truly working. This structured approach ensures you are building a sustainable business, not just a leaky bucket of one-time users. The full article details how to fine-tune these steps.

The guide separates HealthTech GTM into three distinct models. How should a founder trying to operate a hybrid model, like a telehealth platform that also sells B2B corporate packages, structure their team to avoid failure?

Operating a hybrid HealthTech model is exceptionally challenging because it forces you to run two fundamentally different GTM systems simultaneously. The biggest mistake is to use a single team to manage both a high-velocity consumer motion and a slow-burn enterprise sales process. This almost always leads to the slower B2B cycle being starved of resources and attention, causing it to fail. The key is to create two distinct, specialized GTM pods with separate leadership, budgets, and KPIs. You must build two parallel engines: The Consumer Telehealth Pod: This team should be led by a consumer marketing expert and consist of performance marketers, content creators, and product managers. Their dashboard will track metrics like cost per consultation (target: Rs 1,200 to Rs 2,500), patient LTV, and repeat usage rate. Their focus is scalable, low-touch acquisition and retention.The B2B Corporate Sales Pod: This team needs an experienced enterprise sales leader and should be staffed with B2B sales executives who are skilled at navigating corporate procurement. Their dashboard will track pipeline value, sales cycle length, and annual contract value. Their focus is high-touch, relationship-based selling. By treating them as separate business units, you allow each to succeed based on the unique rules of its model. Exploring the full analysis will help you allocate resources effectively.

Many consumer digital health platforms, such as wellness and fitness apps, struggle because their high customer acquisition costs make initial sales unprofitable. How can these companies avoid this common pitfall and build a sustainable business?

Wellness and fitness apps face a steep climb to profitability due to high acquisition costs, which upGrowth estimates can reach Rs 2,500 to Rs 4,000 per customer. The core problem is that monetizing behavior change is difficult, and initial subscription payments rarely cover this expense. The solution is to build a GTM system obsessed with driving long-term engagement and maximizing lifetime value, ensuring that users stick around long enough for their recurring payments to generate a profit. To avoid this pitfall, companies must shift from an acquisition-only mindset to a retention-first strategy: Front-load Value in Onboarding: The first few sessions are critical. Create a highly personalized and motivating onboarding experience that demonstrates clear value and sets the user on a path to achieving a small, early win.Engineer for Community and Accountability: Build features that foster a sense of community, like group challenges, leaderboards, or direct coaching. Social accountability is a powerful retention tool that keeps users engaged far longer than solo efforts.Diversify Revenue Streams: Do not rely solely on a single subscription. Offer premium content, one-on-one coaching, branded merchandise, or partnerships with nutrition services to increase the average revenue per user (ARPU). Success in this space depends on becoming an indispensable part of a user's daily routine. Uncover more strategies for boosting LTV in the full article.

Given the trend toward value-based care and the increasing need for data-driven clinical outcomes, how might the GTM strategy for B2B hospital sales evolve, and what should founders prepare for in the coming years?

The go-to-market strategy for B2B hospital sales is shifting from selling features to proving economic and clinical value. As healthcare moves toward value-based care, hospital procurement decisions will increasingly depend on a solution's ability to demonstrate measurable improvements in patient outcomes and reductions in cost. Founders must prepare for a future where a successful GTM is built on a foundation of robust clinical evidence and a clear return on investment proposition. The future of B2B healthtech sales will require a more sophisticated approach: From Product Demos to ROI Calculators: Sales conversations will center less on software features and more on financial models that project savings or revenue gains for the hospital. Your sales team will need to be fluent in healthcare economics.Clinical Validation as a Prerequisite: Having peer-reviewed studies or strong real-world evidence will no longer be a bonus, but a requirement to even begin a sales conversation. The 6 to 19 month sales cycle will increasingly involve a formal clinical validation phase.Rise of 'Device as a Service' and Risk-Sharing Models: Instead of large upfront contracts, hospitals will favor pricing models where payment is tied to performance metrics. Your GTM must adapt to support these more complex, long-term partnerships. This evolution means your GTM must be deeply integrated with your clinical and product teams. Prepare for this shift by reading the full analysis on emerging trends.

Looking at the different acquisition costs and sales cycles, what do these figures imply about the capital requirements and fundraising strategies for startups pursuing each of the three HealthTech business models discussed?

The stark differences in acquisition costs and sales cycles across the three HealthTech models have profound implications for your fundraising strategy and overall capital requirements. Your business model directly dictates how much cash you need to raise and how you should pitch your growth story to investors. Misaligning your fundraising plan with your GTM reality is a recipe for running out of money before you find product-market fit. Here is how capital needs differ by model: Digital Health Platforms: These businesses require significant upfront capital for marketing to achieve scale. While the CAC per user (Rs 1,500 to Rs 3,500) is low, you need millions of users. Your pitch to investors will focus on LTV:CAC ratios and payback periods, showing a clear path to profitability through retention.Telehealth: Capital needs are similar to platforms, with a heavy emphasis on marketing spend. However, the path to profitability can be faster if you can successfully implement subscription models that generate predictable, recurring revenue early on.B2B Hospital Sales: This model is the most capital-intensive in the short term. With a CAC of Rs 8 lakh to Rs 15 lakh and a sales cycle of up to 19 months, you need enough runway to survive for over a year without significant revenue. Your fundraising pitch will emphasize long-term contract value and market defensibility. Understanding these dynamics is essential for building a realistic financial plan. The full article provides more context on matching your model to your funding.

How should a HealthTech founder in the Indian market approach the regulatory landscape, and why is it essential to verify government sources and seek qualified counsel before finalizing a GTM plan based on this guide?

Navigating the Indian HealthTech regulatory landscape requires continuous vigilance and expert guidance, as rules around data privacy, telemedicine, and medical devices are dynamic. While this guide provides a commercial framework, it is not a substitute for legal advice. Finalizing a go-to-market plan without verifying the latest government guidelines and consulting with legal experts is a significant risk that can lead to costly rework or even operational shutdowns. Your GTM plan must be built on a compliant foundation. Key considerations for the Indian market include: Telemedicine Practice Guidelines: These rules, issued by the Ministry of Health and Family Welfare, dictate how doctors can provide remote consultations, what medications can be prescribed, and the required standards for technology platforms.Digital Personal Data Protection Act (DPDPA): Health data is classified as sensitive personal data, and your platform must comply with strict rules regarding its collection, storage, and processing, including explicit user consent.Medical Device Rules: If your HealthTech solution includes hardware or is classified as 'Software as a Medical Device' (SaMD), it will fall under the purview of the Central Drugs Standard Control Organisation (CDSCO), requiring specific registrations and compliance. Always use the information in this guide as a strategic starting point, but engage qualified legal and regulatory counsel to ensure your GTM plan is fully compliant. Learn where to find official sources in the complete overview.

The guide estimates an acquisition cost of Rs 1,200 to Rs 2,500 for a telehealth patient. What specific marketing channels and tactics are typically used to acquire patients at this cost, and how is this investment justified?

Acquiring a telehealth patient for Rs 1,200 to Rs 2,500 requires a blended and highly optimized digital marketing strategy. This investment is justified not by a single consultation fee but by the projected lifetime value of a patient who becomes a repeat user. The entire acquisition funnel must be designed to attract users with a high propensity for recurring healthcare needs, making the initial spend a down payment on future revenue. To achieve this target CAC, telehealth platforms typically employ a mix of channels: Search Engine Marketing (SEM): Bidding on high-intent keywords related to specific symptoms or conditions (e.g., 'online doctor for cold and flu') captures users at their moment of need.Social Media Advertising: Using targeted ads on platforms like Meta and Google to reach specific demographic segments, often focusing on common primary care issues or mental health support.Content Marketing and SEO: Creating authoritative blog posts, articles, and health guides that rank organically for common health queries, attracting users who are researching symptoms and establishing the platform as a trusted resource.Corporate Partnerships: Offering telehealth services as a benefit to employees of partner companies provides access to a large pool of potential users at a very low marginal acquisition cost. This multi-channel approach is critical to building a scalable and cost-effective patient acquisition engine. Dive deeper into channel strategy in the complete guide.

HealthTech GTM by Business Model: Digital Health, Telehealth and B2B Hospital Sales

Amol Ghemud
HealthTech GTM by Business Model: Digital Health, Telehealth and B2B Hospital Sales
Published: January 16, 2026

Contributors: Amol Ghemud
Published: January 16, 2026

Summary

HealthTech GTM has to be built around your revenue model, not your customer label. Digital health platforms live or die on repeat purchase, telehealth on consultation frequency, and B2B hospital sales on consensus across a 6 to 19 month cycle. This guide sets the 3 models side by side with Indian market and regulatory data verified in September 2026.

In This Article

Share On:

HealthTech founders keep making the same expensive assumption: that GTM strategy follows customer type rather than business model. They ship a product, pick a target segment and start buying traffic without accepting that the way you earn money sets everything downstream. A consumer telemedicine app and a hospital SaaS product both sell into “healthcare”, and they still need completely different healthtech GTM systems.

Digital health platforms earn transaction fees or subscriptions from individual users. Telehealth earns revenue per consultation or through subscription packages. B2B hospital sales close annual contracts through multi stakeholder decision processes. Each model carries its own unit economics, sales cycle and scaling dynamics. Run a consumer playbook at enterprise buyers and you burn capital. Run hospital sales tactics at consumer telehealth and you kill velocity. That is why healthtech GTM has to be designed model by model.

HealthTech GTM is the go to market system you build around your revenue model, not around your customer label. Digital health platforms optimise for repeat transactions and recoverable acquisition cost. Telehealth optimises for consultation frequency and stored patient history. B2B hospital sales optimise for consensus across 6 to 10 stakeholders over a 6 to 19 month cycle.

This guide covers commercial strategy for healthtech companies. It is not medical, legal or regulatory advice. Indian health data rules, telemedicine guidelines and medical device rules change, so verify the government sources cited here and take qualified counsel before you build a launch plan on them. Figures are current as of September 2026.

The 3 healthtech business models at a glance

Place your company in 1 of the 3 models below before you spend on channels. Revenue structure, sales cycle and who signs the contract decide almost every downstream choice, from headcount mix to the metric your board tracks each month.

HealthTech GTM by business model: revenue structure, sales cycle and acquisition cost (cost and cycle ranges are upGrowth estimates, September 2026)
Business model	Primary revenue source	Sales cycle	Acquisition cost	Core GTM challenge	Retention driver
Digital health platforms	Transaction fees and subscriptions	Days to weeks	Rs 1,500 to Rs 3,500 per customer	Acquisition cost outruns order value until purchases repeat	Refill subscriptions, reminders, loyalty credit
Telehealth	Consultation fees, subscriptions, corporate packages	Days to weeks	Rs 1,200 to Rs 2,500 per patient	Turning a single consultation into a repeat habit	Unlimited plans, linked pharmacy, stored records
B2B hospital sales	Annual contracts, SaaS, Device as a Service	6 to 19 months	Rs 8 lakh to Rs 15 lakh per deal	Multi stakeholder consensus and integration risk	Clinical outcomes, workflow lock in, contract term

The gap in the sales cycle column is the one that breaks companies. A model that measures payback in weeks and a model that measures it in quarters cannot share a team, a budget line or a dashboard, and running both from a single pool of people usually starves the slower one.

Digital health platforms: consumer acquisition at scale with a retention problem

Digital health platforms win on the second purchase, not the first. E-pharmacies, wellness apps, health trackers and patient engagement tools sell direct to consumers, so healthtech GTM here optimises for high volume acquisition plus retention mechanics that lift frequency and lifetime value.

Unit economics: the first order rarely pays for itself

Acquisition cost for a digital health platform typically lands between Rs 1,500 and Rs 3,500 per customer. E-pharmacy sits lower, around Rs 1,200 to Rs 2,000, because purchases repeat on their own. Wellness and fitness apps sit higher, around Rs 2,500 to Rs 4,000, because behaviour change is harder to monetise. These are upGrowth estimates from September 2026, not published benchmarks.

The structural problem is low ticket size. E-pharmacy order values cluster around Rs 450 to Rs 800, annual wellness subscriptions around Rs 999 to Rs 2,499, and diagnostic bookings around Rs 1,200 to Rs 2,500. After acquisition cost, platform fees and first order discounts, transaction 1 is usually a loss. Profit starts when the customer comes back inside 60 to 90 days, so the model has to solve frequency, not just conversion.

Scale on its own does not fix this. India’s large e-pharmacy platforms built volume through deep first order discounting, then spent years re engineering retention to make that volume pay. Treat order growth as an input and contribution margin per repeat customer as the output you manage.

GTM channels: performance marketing with retention infrastructure behind it

Acquisition for this model runs on a predictable channel set. What separates the platforms that survive is the retention layer sitting behind the channel spend, which is where most of the channel and funnel execution work actually happens.

Search ads against high intent queries such as buying medicines online or booking a blood test
Meta and Instagram campaigns built around specific conditions, life stages and city clusters
Partnerships with doctors, nutritionists and fitness creators who carry clinical credibility
Content and tools such as symptom explainers, dosage guides and test preparation checklists
Affiliate and bundled distribution through corporate wellness programmes and insurers

The retention side needs the same investment. Refill subscriptions priced below one off purchase. Reminders tied to the prescription cycle, not a generic calendar. Tracking features that give people a reason to open the app between purchases. Loyalty credit that funds the next order. Reorder flows on WhatsApp for repeat buyers.

Segments: urban millennials versus assisted elderly buyers

Urban millennial and Gen Z buyers treat digital health as convenience. They adopt fast, respond to performance marketing and expect app native service, so GTM for them optimises for velocity and referral. Older buyers often need assisted ordering, a family member in the loop, or an institutional route through senior living communities and clinics. That segment is relationship led and needs phone support, not a faster checkout.

Stigmatised categories behave differently again. In sexual wellness, hair loss and mental health, the privacy of a digital purchase is itself the reason people switch from a pharmacy counter. GTM for these categories leans on discreet packaging, confidential consultations and support staff trained to avoid judgement, and it should never promise a clinical outcome the product cannot evidence.

Telehealth GTM: consultation frequency and platform stickiness

Telehealth revenue follows consultation frequency, so healthtech GTM has to turn 1 consultation into a habit. IMARC Group values India’s telemedicine market at USD 3.76 billion in 2025, projected to reach USD 20.02 billion by 2034 at a 20.42% CAGR, in a report last updated in August 2026.

Revenue models: pay per consultation versus subscription

Transactional pricing charges per consultation and scales with demand. General physician consultations commonly sit around Rs 299 to Rs 499, specialists such as dermatologists or gynaecologists around Rs 499 to Rs 799, and super specialists at Rs 999 and above. Revenue is easy to attribute and impossible to forecast, because nothing obliges a patient to come back. These ranges are upGrowth estimates from September 2026.

Subscriptions bundle unlimited consultations for a monthly fee, commonly between Rs 499 and Rs 1,499. That creates predictable revenue and lifts lifetime value, but only pays off when household consultation frequency is high enough to beat pay per use. Corporate and insurer funded packages are the third route, and they shift acquisition from individual marketing to enterprise distribution.

Mobile first execution, and the compliance layer under it

Telehealth is a mobile product before it is a medical one. Push reminders for follow ups, asynchronous chat that removes waiting, prescription handoff into pharmacy fulfilment, and stored health records that make switching platforms costly. Cloud based deployment is the largest deployment segment at 49% share in 2025 according to IMARC Group, which is why uptime and data handling belong in the sales narrative rather than the appendix.

Compliance is part of the offer, not a tax on it. The Telemedicine Practice Guidelines were issued by the Government of India on 25 March 2020 and set the norms and protocols for telemedicine practice.

The Digital Personal Data Protection Rules, 2025 were notified by the Ministry of Electronics and Information Technology on 14 November 2025, with an 18 month phased compliance window, a requirement that consent managers be India based companies, and a 90 day deadline to answer access, correction and erasure requests. Build those into the roadmap early and your telehealth sales team can sell them, as covered in our guide to trust and compliance for healthtech buyers.

Geographic expansion: where telehealth demand actually sits

North India leads the Indian telemedicine market with a 37% share in 2025, on IMARC Group figures. Bengaluru, Chennai and Hyderabad remain major build hubs for health platforms, which is a different question from where consultations get bought. Expansion plans that assume the 2 maps overlap tend to overspend in the south and under invest in the north.

Tier 2 and Tier 3 expansion needs its own execution, not a translated version of the metro plan. Vernacular interfaces and vernacular doctors. Low bandwidth modes that survive patchy connectivity. Local clinic and pharmacy partners for the physical half of the journey. Prices that match local willingness to pay.

Government rails: ABDM and eSanjeevani as healthtech GTM accelerators

India’s public digital health rails are distribution and credibility you do not have to build. The Ayushman Bharat Digital Mission crossed 90 crore health accounts by May 2026, and over 100 crore health records are now linked to those accounts.

What ABDM integration changes for each model

More than 450 public and private health technology solutions had integrated with the ABDM ecosystem by May 2026, and linked records doubled from 50 crore in February 2025 to over 100 crore in 15 months. For a digital health platform, consent based record access removes onboarding friction. For telehealth, it moves prescriptions and diagnostic reports between providers without a fax machine. For B2B, interoperability is simply the price of entry.

The GTM move is to treat this infrastructure as a channel. Integrate with the published APIs instead of building a walled garden. Partner with public health centres to run consultations where private supply is thin. Work with state programmes deploying telemedicine nodes at primary health centres. Each of those routes lowers acquisition cost and borrows trust that a private brand cannot buy.

Competing with a free public telehealth service

eSanjeevani, the national telemedicine service, had delivered teleconsultations to 10 crore beneficiaries as of February 2023, largely through health and wellness centres focused on primary care. A private platform does not win that comparison on price. It wins on specialist and super specialist access, shorter waits, diagnostics and pharmacy in a single journey, employer funded packages and availability outside clinic hours.

B2B hospital sales: enterprise complexity with recurring revenue

B2B healthtech GTM is a consensus problem, not a pitch problem. Selling software, devices or services to hospitals, diagnostic labs and payers runs on long cycles, large deal values and procurement rules that consumer growth teams never encounter.

Sales cycles and the buying committee

Enterprise healthtech deals in India commonly run 6 to 19 months from first conversation to signature, on our experience across healthtech go to market engagements. That is structure, not inefficiency. A single purchase usually involves 6 to 10 people: the owner or promoter who signs, the CIO who judges integration, the CFO who tests payback, the medical director who validates clinical utility, the procurement committee that runs the process, and the security team that audits data handling.

Each of them evaluates a different thing, and each can stop the deal. The owner wants revenue impact and cost savings. The CIO worries about the existing hospital information system. Clinicians worry about workflow disruption and patient safety. Sales motions that address only the economic buyer stall in late stage, which is the most expensive place to lose. Our healthtech marketing case studies cover how we approach that work.

OPEX versus CAPEX: the pricing decision that decides the deal

Indian hospital buyers consistently prefer operating expenditure to capital expenditure. Rs 5 lakh a year is easier to approve than Rs 50 lakh once, even when total cost of ownership is identical, because it fits cash flow, spreads risk and clears a lower approval threshold. Price the same product both ways and the subscription version closes faster.

Device as a Service extends the logic to hardware. The manufacturer finances the equipment, handles maintenance and commits to availability while the hospital pays monthly against usage or outcomes. That works best for diagnostics, patient monitoring and imaging. The pitch stops being “buy this machine” and becomes “keep this capacity running at a predictable cost per test”.

Integration: the deal blocker nobody budgets for

Indian hospitals run legacy information systems with little standardisation. A product that cannot export results into the existing system dies in pilot, however good the underlying model is. FHIR compliant, plug and play integration is what separates a pilot from a rollout.

Build integration into the offer rather than the contract’s fine print. Pre built connectors for the hospital information systems you meet most often. An implementation team that owns the hospital side of the work and the staff training. API documentation good enough for a hospital IT team to use without you. Success metrics tied to completed integration and live usage, not to a signed pilot.

Clinical validation and licensing are entry gates, not extras

Hospitals expect clinical evidence before they adopt. A diagnostic model trained only on Western datasets and never validated on Indian patient populations gets rejected early. Validation means testing on Indian demographic data, publishing results, earning endorsements from respected clinicians or institutions, and running research within the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants published by the Indian Council of Medical Research in 2017.

Medical devices carry a separate gate. Under the Medical Devices Rules, 2017, the Central Drugs Standard Control Organisation classifies devices into risk classes A, B, C and D. The Central Licensing Authority handles imports of all classes and manufacturing of Class C and D devices, while State Licensing Authorities handle manufacturing of Class A and B devices and the sale and distribution of all classes. Plan 6 to 12 months of validation and licensing work into the GTM timeline before you scale a sales team against it.

MedTech GTM: from hardware margin to digital ROI

MedTech GTM is moving from selling boxes to selling uptime. The National Medical Devices Policy, 2023 put India’s medical devices sector at USD 11 billion in 2020 and set a target of USD 50 billion by 2030, per the Cabinet announcement of 26 April 2023.

The hardware profitability squeeze

Commodity hardware competes on price against cheaper imports, gross margins compress, and the relationship ends at installation. Selling a diagnostic device for Rs 10 lakh books revenue once and creates nothing recurring. The economics only improve when something billable keeps running after the machine is delivered.

Connected care is where that recurring line comes from. Remote monitoring devices that bill a subscription. Cardiac monitors that stream to a physician dashboard for a monthly fee. SaaS for hospital operations, ICU dashboards or radiology workflow on annual contracts. Predictive maintenance sold as guaranteed availability rather than a service call.

From device sales to uptime as a service

Traditional MedTech sells through tenders, distributors and direct hospital relationships, paid upfront. The newer model sells availability on an annual fee, which changes the commercial motion. Field teams argue total cost of ownership rather than sticker price. Demos show dashboards, not only specifications. Contracts carry service levels. Customer success owns renewal instead of walking away at installation.

Keep any availability or cost saving commitment tied to a contract you can evidence. Vague uptime promises are the fastest way to lose a procurement committee that has heard them before. The same discipline applies across verticals, and edtech GTM by customer type is worth reading alongside this.

PLI and domestic manufacturing as a tender advantage

The Production Linked Incentive scheme for medical devices runs from FY2022-23 to FY2026-27 with a budgetary outlay of Rs 3,420 crore. Production has started for 55 products across 22 commissioned greenfield projects, with cumulative sales of Rs 12,344.37 crore including Rs 5,869.36 crore of exports as of September 2025, per the Department of Pharmaceuticals update of 5 December 2025.

Medical device parks have been approved at Greater Noida in Uttar Pradesh, Ujjain in Madhya Pradesh and Kanchipuram in Tamil Nadu, with land allotted to 194 manufacturers as of September 2025. For a domestic MedTech company, that is a GTM lever: local manufacturing credentials in public tenders, competitive landed cost against imports, and hardware bundled with software so a commodity device still earns recurring revenue.

HealthTech GTM FAQs

Which healthtech business model is the most profitable?

B2B hospital sales carry the highest gross margins once they scale, because annual contracts and switching costs keep churn low. They also take the longest to pay back, since cycles run 6 to 19 months before revenue starts. Digital health platforms grow revenue faster but carry thinner margins from acquisition cost and discounting. Telehealth sits in the middle and only works when consultation frequency holds up. These figures are upGrowth estimates from September 2026.

Should a healthtech startup build a B2C or B2B go to market plan first?

Start with the model your founding team can actually execute. B2C needs performance marketing depth, retention features inside the product and capital to fund acquisition before payback. B2B needs enterprise sales experience, patience for long procurement cycles and comfort with multi stakeholder buying. Most companies prove a single model profitably, then add the other as a separate business line with its own team, budget and metrics.

What does a digital health go to market strategy need to cover in India?

4 things. Acquisition economics, because a first order rarely covers acquisition cost. Retention mechanics such as refill subscriptions, reminders and loyalty credit, since profit comes from repeat purchase. Compliance, including the Telemedicine Practice Guidelines issued in March 2020 and the Digital Personal Data Protection Rules notified in November 2025. And interoperability, because ABDM integration now shapes how patient records move between apps and providers.

How do telehealth platforms compete with free government services like eSanjeevani?

They compete on access and continuity rather than price. eSanjeevani is a free public service that had delivered teleconsultations to 10 crore beneficiaries as of February 2023, per the Press Information Bureau, and it runs largely through public health centres focused on primary care. Private platforms monetise what that system does not prioritise: specialist access, shorter waits, diagnostics and pharmacy in a single journey, employer funded packages and availability outside clinic hours.

What makes B2B hospital sales cycles so long in India?

Decision authority usually sits with owners or promoters who evaluate purchases personally rather than delegating. A single deal needs technical validation from IT, clinical validation from doctors, financial approval from the CFO, procurement compliance and a security review of data handling. Pilots add months of their own, and budget cycles tied to the financial year create blackout periods. Compressing those stages signals inexperience and stalls the deal.

Is hardware or SaaS the better GTM focus for MedTech startups?

Neither on its own. Pure hardware runs into commoditisation and price pressure from imports. Pure software struggles when hospitals will not pay for a licence with no equipment attached. The model that holds up bundles the device with connectivity, dashboards and service, so a single sale becomes recurring revenue through remote monitoring and maintenance. That structure also matches the hospital preference for operating expenditure over capital expenditure.

Your next move: match the GTM model to how you earn

The question is not consumers or hospitals. It is whether your go to market system matches your revenue structure, sales cycle and buying committee. Digital health platforms optimise for repeat purchase. Telehealth optimises for consultation frequency. B2B hospital sales optimise for consensus and integration.

Start by writing down which of the 3 models pays your bills today, then audit whether your team, budget and metrics actually serve it. If 2 models are running from a single budget, split them before you scale either. The wider frameworks sit in our healthtech go to market strategy guide, and the service view is on our go to market strategy page.

Working through a model decision right now? Book a strategy call with upGrowth and bring your current acquisition cost, sales cycle and repeat rate, or get in touch with the numbers you have.

For Curious Minds

Aligning your go-to-market strategy with your business model, not just your customer type, is the most crucial decision a HealthTech founder can make. The way you earn revenue dictates your entire commercial system, from sales cycle and team structure to the metrics that matter. A consumer telemedicine app and a hospital SaaS platform both serve 'healthcare', but their paths to scale are fundamentally different and require separate playbooks. Mixing them leads to wasted capital and stalled growth. Your business model determines the GTM system you need to build:

Digital Health Platforms: With revenue from transaction fees and subscriptions, the GTM must solve for a low initial order value. The focus is on driving repeat purchases through retention mechanics like refill reminders and loyalty credits to recover an acquisition cost of Rs 1,500 to Rs 3,500 per customer.
Telehealth: Revenue comes from consultations or packages. The GTM challenge is turning a single interaction into a habit. Success depends on features like unlimited plans and stored records to build long-term patient relationships.
B2B Hospital Sales: Based on annual contracts, this model requires a GTM that can navigate a 6 to 19 month sales cycle and gain consensus from up to 10 stakeholders. The focus is on demonstrating clinical outcomes and achieving workflow lock-in.

Failing to build your GTM around these distinct economic realities is the most common reason healthtech companies fail to scale. Discover how to match your commercial strategy to your revenue structure in the complete guide.

Generated by AI

Connect us to get more insights

About the Author

Amol Ghemud

Optimizer in Chief

Amol has helped catalyse business growth with his strategic & data-driven methodologies. With a decade of experience in the field of marketing, he has donned multiple hats, from channel optimization, data analytics and creative brand positioning to growth engineering and sales.

In This Article